Ebola
-에볼라 바이러스 취사율
Ebola virus is one of the four ebolaviruses known to cause disease in humans. It has the highest case-fatality rate of these ebolaviruses, averaging 83% since first described in 1976, although fatality rates up to 90% have been recorded in one epidemic (2002–03). There have also been more outbreaks of ebola virus than of any other ebolavirus. - 사망자
26 September 2014 – The United Nations World Health Organization (WHO) today said it is intensifying its cooperation with a wide range of partners trying to accelerate work on experimental therapies and vaccines as it announced that Ebola has now sickened more than 6,500 and killed more than 3,000.
-신약 ZMapp
ZMapp is an experimental biopharmaceutical drug comprising three humanized monoclonal antibodies under development as a treatment for Ebola virus disease. The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak and was credited as helping save lives, but it has not been subjected to a randomized clinical trial to prove its safety or its efficacy.
-임상실험을 거치지않은 ZMapp 을 허용한 WHO
ZMapp has not yet been tested in a clinical trial to support widespread usage in humans.[33] In light of the 2014 Ebola outbreak, an expert panel from the World Health Organization (WHO) announced on August 12, 2014, "In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention."
-임상실험 과정
Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and
Ebola virus is one of the four ebolaviruses known to cause disease in humans. It has the highest case-fatality rate of these ebolaviruses, averaging 83% since first described in 1976, although fatality rates up to 90% have been recorded in one epidemic (2002–03). There have also been more outbreaks of ebola virus than of any other ebolavirus. - 사망자
26 September 2014 – The United Nations World Health Organization (WHO) today said it is intensifying its cooperation with a wide range of partners trying to accelerate work on experimental therapies and vaccines as it announced that Ebola has now sickened more than 6,500 and killed more than 3,000.
-신약 ZMapp
ZMapp is an experimental biopharmaceutical drug comprising three humanized monoclonal antibodies under development as a treatment for Ebola virus disease. The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak and was credited as helping save lives, but it has not been subjected to a randomized clinical trial to prove its safety or its efficacy.
-임상실험을 거치지않은 ZMapp 을 허용한 WHO
ZMapp has not yet been tested in a clinical trial to support widespread usage in humans.[33] In light of the 2014 Ebola outbreak, an expert panel from the World Health Organization (WHO) announced on August 12, 2014, "In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention."
-임상실험 과정
Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and